Herpes simplex virus hepatitis in mice: effects of treatment with trisodium phosphonoformate.
Clinical isolates of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) induced focal necrotic hepatitis in ICR/Schö mice. The extent of the hepatitis could be considerably reduced by trisodium phosphonoformate (PFA) administered for 3 days in a daily dose of 400-600 mg/kg. The HSV hepatitis in mice could serve as a suitable model for testing antiherpetic drugs.